Rexahn Preclinical Data for Novel Anti-Cancer Compound RX-3117 Published

Rexahn Preclinical Data for Novel Anti-Cancer Compound RX-3117 Published — ROCKVILLE, Md.–(BUSINESS WIRE)– Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing potential best-in-class…

More Drug Treatment News Articles Information…